Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03509350 · ClinicalTrials.gov registry record · Phase 3
Vitamin C, Thiamine, and Steroids in Sepsis
A Phase 3 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 3
- Development phase
- 501
- Enrollment target
NCT03509350: Completed Phase 3 study, sponsored by Emory University.
NCT03509350 is a Phase 3 study that has completed, run by Emory University. The registered enrollment target is 501 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (35% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03509350, a Phase 3 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 501 participants
- Enrollment target
Study Summary
The VItamin C, Thiamine And Steroids in Sepsis (VICTAS) Study is a double-blind, placebo-controlled, adaptive randomized clinical trial designed to investigate the efficacy of the combined use of vitamin C, thiamine and corticosteroids versus indistinguishable placebos for patients with sepsis. The objective of this study is to demonstrate the efficacy of combination therapy using vitamin C, thiamine and corticosteroids in reducing mortality and improving organ function in critically ill patients with sepsis.
Primary Outcome
The primary outcome measure is VVFD in the first 30 days after the start of treatment. The endpoint was recorded to the nearest day. Participants who died are scored zero days, even if there was a period during which the participant was alive and free of vasopressors and mechanical ventilation. Participants who must return to ventilation and/or vasopressors had their counters reset at zero days.
Interventions
- DRUG Thiamine
- DRUG Vitamin C
- DRUG Hydrocortisone
- DRUG Vitamin C Placebo
- DRUG Thiamine Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 501 participants |
| Start Date | 2018-08-22 |
| Est. Completion | 2020-01-29 |
| Phase | Phase 3 |
What the finished NCT03509350 record still lists
NCT03509350 is an interventional study that assigns participants to a tested intervention. The registered 501 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (35% lower).
The record links to 0 conditions, and to 5 interventions - of which Thiamine is the first listed.
NCT03509350 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03509350 about?
NCT03509350 is a clinical study titled "Vitamin C, Thiamine, and Steroids in Sepsis". The VItamin C, Thiamine And Steroids in Sepsis (VICTAS) Study is a double-blind, placebo-controlled, adaptive randomized clinical trial designed to investigate the efficacy of the combined use of vitamin C, thiamine and corticosteroids versus indistinguishable placebos for patients with sepsis. The ...
What is the current status of trial NCT03509350?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 501 participants. The study started on 2018-08-22. Estimated completion is 2020-01-29.
What interventions are being tested in trial NCT03509350?
The interventions under investigation include: Thiamine (DRUG), Vitamin C (DRUG), Hydrocortisone (DRUG), Vitamin C Placebo (DRUG), Thiamine Placebo (DRUG).
Who is sponsoring clinical trial NCT03509350?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03509350's enrollment target sits among peer trials
501 743rd of 2000 higher than 1,257 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04442022 · 501 participants · Phase 2
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT06934525 · 501 participants · NA
Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings
- NCT05646381 · 502 participants · Phase 2
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
- NCT05897632 · 502 participants · NA
CARE-CP (Testing a Cardiovascular Ambulatory Rapid Evaluation for Patients With Chest Pain)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI